Roth Capital Has Optimistic Outlook of Clene FY2027 Earnings

Clene Inc. (NASDAQ:CLNN) – Roth Capital lifted their FY2027 earnings per share (EPS) estimates for shares of Clene in a report issued on Monday, March 24th. Roth Capital analyst J. Aschoff now expects that the company will post earnings per share of $6.41 for the year, up from their previous estimate of $6.30. The consensus estimate for Clene’s current full-year earnings is ($5.19) per share. Roth Capital also issued estimates for Clene’s FY2028 earnings at $9.04 EPS and FY2029 earnings at $12.47 EPS.

Clene (NASDAQ:CLNN) last announced its quarterly earnings results on Monday, March 24th. The company reported ($1.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.21) by ($0.46). Clene had a negative net margin of 8,556.77% and a negative return on equity of 1,106.30%. The business had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.13 million.

Several other research analysts have also recently weighed in on the stock. HC Wainwright reissued a “buy” rating and set a $31.00 price objective on shares of Clene in a report on Monday. D. Boral Capital reissued a “buy” rating and set a $23.00 price target on shares of Clene in a report on Monday. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $55.25.

Clene Stock Performance

CLNN opened at $3.54 on Wednesday. The company’s 50-day simple moving average is $4.49 and its two-hundred day simple moving average is $4.88. The stock has a market capitalization of $29.47 million, a P/E ratio of -0.67 and a beta of 0.27. Clene has a 52-week low of $3.37 and a 52-week high of $9.20.

Institutional Trading of Clene

Several large investors have recently added to or reduced their stakes in CLNN. Parsons Capital Management Inc. RI purchased a new position in shares of Clene during the 4th quarter worth $194,000. SBI Securities Co. Ltd. bought a new position in Clene in the 4th quarter worth $69,000. Geode Capital Management LLC lifted its position in Clene by 52.9% during the fourth quarter. Geode Capital Management LLC now owns 65,112 shares of the company’s stock valued at $346,000 after purchasing an additional 22,539 shares in the last quarter. Renaissance Technologies LLC bought a new stake in Clene during the fourth quarter valued at about $96,000. Finally, Fullcircle Wealth LLC purchased a new stake in Clene in the fourth quarter worth about $69,000. 23.28% of the stock is currently owned by institutional investors.

Clene Company Profile

Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.